Quantcast

Anti-Wnt Compound (SSTC-104) to Treat Synovial Sarcoma?


#1

A recent study shows that SYT-SSX2, the mutant gene in synovial sarcoma, activates the Wnt pathway which leads to disease progression:

http://www.ncbi.nlm.nih.gov/pubmed/23921231

In the study, they used a compound designed by Stemsynergy and managed to prevent tumor progression in mice:

http://www.fortmilltimes.com/2013/08/08/2877295/stemsynergy-announces-breakthrough.html

Human trials next?


#2

Some news about the company that makes SSTC-104:

http://www.tennessean.com/story/money/2014/06/16/stem-cell-researcher-moves-cool-springs-center/10639485/

http://www.fortmilltimes.com/2014/06/16/3549207/stemsynergy-therapeutics-invited.html

Hopefully, this will help them start human trials...